PORT WASHINGTON, N.Y., March 22, 2011 - Pall Corporation (NYSE:PLL) will showcase its newest lineup of leading-edge products and services to enhance bioprocessing workflows next week at Interphex 2011. The company will demonstrate how its separation systems and single-use technologies can be “Your Path to Bioprocess Success” in drug development and production. Interphex is the foremost gathering of pharma and biotech professionals. The show takes place March 29-31 at New York’s Javitz Convention Center.
At Pall’s booth #2821, visitors will explore critical paths in bioprocessing and discover new products and services that streamline workflows and maximize efficiencies in media preparation, cell culture, clarification and cell harvest, downstream purification, contaminant control, polishing, formulation, filling, and quality control.
The company will highlight its Allegro™ platform which provides single-use processing solutions, technical support, and validation services. Pall continues to strengthen its single-use product portfolio with a focus on consistent materials of construction that simplify qualification and validation requirements, and ease implementations.
New product highlights include:
Allegro™ 3D single-use mixers – flexible, reliable, impellor-based systems for large-volume applications including vaccine and drug formulation, and mixing viscous fluids. Available as 200 L systems for working volumes from 50 to 200 L, Allegro 3D mixers are also ideal for a wide range of liquid-liquid and solid-liquid mixing applications such as compounding, formulation, buffer and media preparation, and pH/conductivity adjustment. Front-loading of the disposable mixer assembly eases set-up. Mixing data is available for a wide range of industry standard applications, demonstrating fast and complete mixing even for preparations requiring high concentrations and large additions of solids.
Allegro™ 2D pillow-type biocontainers – equipped with a powder port for single-use mixing of solids or liquids in small volume batches (10 to 50 L). They provide a simple way of mixing powders into fluids, using the same proven materials as existing Allegro biocontainers. The transparent mixing container allows users to directly monitor dissolution and mixing.
Kleenpak™ sterile disconnector – the first purpose-designed device for maintaining sterile integrity in any sterile process fluid path before and after tube separation, even in cramped and uncontrolled environments. Its patented locking mechanism disconnects in less than 30 seconds without tools or cutting, eliminating the risks associated with clamping and cutting. The need for capital equipment is also eliminated. Flow paths are permanently sealed to ensure product integrity. Ideal for applications such as disconnecting filled biocontainers of bulk product from filling manifolds, removing used filters from systems, and facilitating in-process disassembly without the need for a laminar flow hood.
Allegro single-use system services will also be featured at Interphex 2011. This comprehensive program, supported by Pall’s Scientific and Laboratory Services, provides technical support and validation for single-use systems from upstream through downstream to formulation and filling. Services include systems validation, components validation, consultancy services, engineering services, Pall’s UpScaleSM program, and after-sales support. Pall’s industry-leading expertise in the area of extractables/leachables determination assists customers through the implementation and validation of single-use systems.
“Pall has pioneered single-use systems for biomanufacturing and proven its technological creativity and service leadership,” said Ken Frank, senior vice president of Pall Corporation and president of Pall’s Biopharmaceutical Division. “This makes Pall an ideal partner for producers of biotherapeutics who are looking to exploit single-use technologies. At Interphex 2011, we present the Path to Bioprocess Success in an inviting, interactive environment that also allows visitors to engage with our newest single-use technologies.”
Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Pall technologies are also used to collect and process blood components and help protect patients from hospital-acquired infections. The company’s membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce.
About Pall Corporation
Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.4 billion for fiscal 2010, is an S&P 500 company with more than 10,000 employees serving customers worldwide. To see how Pall is helping enable a greener, safer, more sustainable future, visit www.pall.com/green.